Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Year: 2019
Type: article
Authors: the BFORE Study Investigators, Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Dragana Milojkovic, Philipp le Coutre, Valentin Garcia-Gutierrez, Rocco Crescenzo, Carla Mamolo, Arlene Reisman, Andreas Hochhaus, Tim H. Brümmendorf
Institutions: The University of Texas MD Anderson Cancer Center, University of Milano-Bicocca, University of Utah, Memorial Sloan Kettering Cancer Center, Singapore General Hospital, Duke-NUS Medical School, Catholic University of Korea, Hammersmith Hospital, Imperial College London, Charité - Universitätsmedizin Berlin, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Pfizer (United States), Jena University Hospital, Universitätsklinikum Aachen, RWTH Aachen University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Pfizer, GlaxoSmithKline, Incyte
OpenAlex ID: W2937928400